Clee Medical, a Swiss neurotechnology startup, has announced the closing of its seed financing round. The goal is to advance the development of ultra-high-resolution real-time imaging solutions for neurosurgery.

Funding Details

The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick, alongside continued support from existing partner Wyss Geneva. The funds raised will be used to expand its development and clinical programs, with the aim of initiating first-in-human clinical studies and accelerating the clinical validation of the Neuro Access platform.

The Neuro Access Platform

Founded in October 2024 by Matt Lapinski and Abed Hammoud, Clee Medical is developing the Neuro Access platform. This combines ultra-high-resolution real-time intraoperative Optical Coherence Tomography imaging with advanced navigation capabilities to support precision neurosurgery. The technology is designed to provide real-time imaging inside the brain, helping surgeons navigate complex anatomy with greater confidence and enabling safer access to deep brain targets for more targeted neurotherapies.

Future Goals

The company’s long-term vision is to enable neurosurgeons to operate with enhanced real-time insight, improving safety, efficiency, and patient outcomes in complex brain procedures. The platform is being developed to support applications including functional neurosurgery and neuro-oncology.